Smarter prostate cancer screening: a blood test that may cut unnecessary biopsies

NCT ID NCT03957252

Ongoing Diagnosis Sponsor: Nanostics Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study is testing whether a new blood test called ClarityDX Prostate can better identify men who have clinically significant prostate cancer. The test is given to men aged 40-75 with elevated PSA levels (3 ng/mL or higher) who are already scheduled for a prostate biopsy. Researchers will compare the test's predictions with actual biopsy results to see if it can reduce false alarms and unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ClarityDX Prostate blood test
What this could lead to: If successful, this test could reduce unnecessary biopsies by more accurately identifying which men with elevated PSA truly have aggressive prostate cancer.
What could go wrong: The test is still being validated and may not prove more accurate than current methods. Results from this observational study will need confirmation in future trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERFORMANCE ASSESSMENT OF NOVEL TEST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERFORMANCE ASSESSMENT OF NOVEL TEST PROSTATE CANCER PROSTATE CANCER SCREENING

Contacts and locations

Show contact details

Locations

Johns Hopkins University

Baltimore, Maryland, 21218, United States
Kipnes Urology Centre

Edmonton, Alberta, T6G 1Z1, Canada
Prostate Cancer Centre

Calgary, Alberta, T2V 1P9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.